Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07718659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra, followed by postoperative ultra-low-dose clozapine to activate the transduced direct pathway, with the goal of improving motor symptoms of Parkinson's disease.
Trial Details
NCT Number NCT07718659
Lead Sponsor Qianfoshan Hospital
Collaborators: Shenzhen Loongen Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Parkinson's Disease (PD), Parkinsonian Disorders
Related terms Central Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases, Parkinson Disease, Parkinsonian Disorders
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov